Testosterone therapy for men over 65 is hormone replacement using injectable, topical, or pellet testosterone to correct a lab-confirmed deficiency, with the goal of restoring energy, muscle mass, bone density, and libido without raising cardiovascular or prostate risk beyond what a man already carries at this age. Men over 65 need a different monitoring cadence than a 45-year-old on the same protocol: cardiovascular history, PSA trends, and hematocrit response carry more weight here than symptom relief alone.
TL;DR
- Testosterone therapy for men over 65 requires two confirmed low morning draws plus PSA, hematocrit, and cardiovascular screening before any prescription.
- Total testosterone below roughly 300 ng/dL, paired with symptoms, is the threshold most labs flag as hypogonadism.
- The TRAVERSE trial (2023, NEJM) followed more than 5,000 men and found no increase in major cardiac events, but flagged higher atrial fibrillation and clot rates.
- Injections allow faster dose correction than pellets if hematocrit climbs, which matters more after 65.
- GoodLife Health re-runs a full Biomarker Audit every 90 days, the monitoring interval this age group actually needs.
- Diagnosis requires two morning draws below roughly 300 ng/dL plus symptoms, not one reading.
- Baseline PSA, hematocrit, and cardiovascular history must be reviewed before the first prescription.
- The 2023 TRAVERSE trial (5,000+ men) found no rise in major cardiac events but higher AFib, clot, and fracture rates.
- Injections give faster dose control than pellets if hematocrit rises, which matters more after 65.
- Hematocrit above roughly 54% is grounds to reduce dose or pause therapy immediately.
- GoodLife Health runs a full Biomarker Audit every 90 days to match this age group's monitoring needs.
Why testosterone therapy matters for men over 65
Testosterone falls roughly 1-2% a year starting in a man's 30s, and by 65 that decline has compounded for three decades. The symptoms overlap heavily with ordinary aging: less muscle, more visceral fat, flatter mood, slower recovery from a workout, a libido that used to show up without being asked. That overlap is exactly why a lab draw matters more here than a symptom checklist. Fatigue at 68 can be low testosterone, undiagnosed sleep apnea, an underactive thyroid, or all three at once.
The stakes are different at 65 than at 45. A man in his mid-60s is more likely to already carry cardiovascular risk factors, an enlarged prostate, or a PSA trend worth watching. That is the population the TRAVERSE trial specifically enrolled in 2023: more than 5,000 men with low testosterone and existing cardiovascular risk, followed to see whether testosterone replacement raised rates of heart attack, stroke, or cardiovascular death. It did not, on the composite primary endpoint. It did show higher rates of atrial fibrillation, blood clots, and bone fractures in the treatment group.
None of that makes testosterone therapy for men over 65 unsafe. It makes monitoring non-negotiable, and it means a protocol written for a 45-year-old cannot be copied onto a 68-year-old without adjustment.
GoodLife Health treats testosterone as one input into a larger cardiometabolic picture, not an isolated fix. Low testosterone, rising ApoB, insulin resistance, and hs-CRP inflammation travel together in this age group, and treating one while ignoring the others misses what is actually driving how a man feels. GoodLife Health runs full hormone and thyroid panels alongside cardiovascular and metabolic markers in 2026 so a testosterone number is never read in isolation.
The step-by-step approach for men over 65
Confirm the deficiency with two morning draws
A single low reading is not a diagnosis. Testosterone follows a daily rhythm and peaks in the early morning, so an afternoon draw can read low in a man whose levels are genuinely normal.
- Draw blood between 7 and 10 a.m., fasting where possible
- Repeat the draw on a separate day before accepting the diagnosis
- Order total testosterone, free testosterone, and SHBG together, since total alone misses men with abnormal binding protein
- Rule out reversible causes first: poor sleep, untreated sleep apnea, uncontrolled blood sugar, opioid use
- Separate the low testosterone symptoms that labs actually confirm from thyroid and mood overlap before assuming TRT is the answer
A clinician who orders and reads both draws, rather than prescribing off one number, is the baseline standard of care at any age.
Screen prostate and cardiovascular risk before the first dose
This step carries more weight at 65 than in any earlier decade. Testosterone does not cause prostate cancer, but it can accelerate growth in an existing undiagnosed tumor, which is why screening comes before the first prescription, not after.
- Get a baseline PSA and prostate exam if none exists from the past 12 months
- Review cardiovascular history in detail: prior heart attack, stroke, clotting disorders, uncontrolled hypertension
- Check baseline hematocrit and hemoglobin, because testosterone raises red blood cell count and starting high compounds stroke risk
- Disclose every current medication, especially anticoagulants and BPH drugs
- Plan the repeat PSA and hematocrit checks at 3 and 6 months before therapy starts, not after
Testosterone does not cause prostate cancer, but it can accelerate growth in an existing undiagnosed tumor, which is why screening comes before the first prescription, not after.
Choose a delivery method that fits real monitoring habits
Injectable, topical, and pellet testosterone all raise levels effectively. The right choice for a man over 65 depends on how consistently he will show up for hematocrit checks, not on which method sounds most modern.
- Intramuscular and subcutaneous injections give the most dose control and are the easiest to reduce quickly if hematocrit rises
- Topical gels avoid needles but carry transfer risk to a spouse or grandchild and absorb inconsistently
- Pellets run for months between insertions but cannot be reversed quickly when a side effect appears
- Compare subcutaneous vs intramuscular testosterone injections directly before committing
- Let the clinician narrow the choice from the full lab panel, not from a menu of delivery options
Start conservative and titrate slowly
Men over 65 respond differently to the same milligram dose than men in their 40s. A starting dose calibrated for a younger patient routinely overshoots in a 68-year-old, pushing hematocrit and estradiol too high too fast.
- Start at the low end of the standard dosing range, not the middle
- Recheck levels at 6 to 8 weeks rather than waiting a full quarter for the first adjustment
- Watch estradiol alongside testosterone, since aromatization increases with age and body fat
- Adjust in small increments, because large jumps make it impossible to isolate what caused a side effect
- Track symptom response, not only the number on the report
Monitor hematocrit and PSA on a fixed schedule
Skipped monitoring is the most common way testosterone therapy for men over 65 goes wrong. Hematocrit above roughly 54% raises clotting risk and is grounds to reduce the dose or pause therapy immediately.
- Recheck hematocrit at 3, 6, and 12 months, then annually
- Recheck PSA on the same schedule, watching the trend rather than any single value
- Watch for signs of elevated red cell count: headaches, visual changes, unusual fatigue
- Reduce dose or donate blood if hematocrit enters the range your clinician flags
- Re-run the full panel rather than a single repeat value, and learn how to read your testosterone lab results so the trend makes sense to you
Hematocrit above roughly 54% raises clotting risk and is grounds to reduce the dose or pause therapy immediately.
Track function, not just the lab number
The point of therapy is how a man moves and feels, not hitting a target figure. Grip strength, afternoon energy, and libido tell you more about whether a dose is right than total testosterone alone.
- Log energy and mood weekly through the first three months of 2026
- Track strength in a repeatable way: same weight, same reps, same walking route
- Note libido and erectile function, which usually lag lab improvement by 6 to 8 weeks
- Watch sleep quality, because untreated apnea blunts the benefit of therapy
- Bring these notes to every follow-up, not just the lab printout
Once manual tracking gets tedious, a membership where the clinician reviews those logs quarterly is the faster path. One flat fee for the doctor. Zero markup on the medicine.
Comparing the options for men over 65
Comparing the options for men over 65
| Option | Best for | Key limitation |
|---|---|---|
| Intramuscular injections | Men who want maximum dose control | More frequent needle sticks; peaks and troughs between doses |
| Subcutaneous injections | Men self-administering with a smaller needle | Still requires weekly or biweekly discipline |
| Testosterone pellets | Men who want infrequent dosing | Cannot be reversed quickly if hematocrit or side effects spike |
| Topical gel or cream | Men who will not use needles | Inconsistent absorption; transfer risk to household members |
| Unmonitored online TRT clinics | Nobody over 65 with cardiovascular risk factors | Commonly skips baseline PSA and hematocrit screening entirely |
| GoodLife Health Cardiometabolic Optimization Membership | Men who want quarterly labs and dose changes tied to real data | Requires a two-month commitment before month-to-month billing |
GoodLife Health's testosterone protocol is built for the over-65 patient specifically: baseline PSA and hematocrit before the first dose, a Biomarker Audit every 90 days, and a physician reading the trend rather than the newest number. Clinical care is delivered by licensed physicians of Beluga Health, P.A., working under GoodLife Health's clinical protocols and licensed in all 50 states.
Common mistakes men over 65 make with TRT
- Skipping the baseline PSA. Starting testosterone without a recent prostate check means nobody catches an existing problem before therapy potentially accelerates it.
- Ignoring hematocrit until symptoms show. By the time headaches or visual changes appear, hematocrit is often already in a range that requires stopping therapy, not just trimming the dose.
- Copying a younger man's protocol. A dose and frequency that suits a 45-year-old routinely overshoots hematocrit and estradiol targets twenty years later.
- Treating testosterone in isolation. Low T rarely travels alone at 65; untreated sleep apnea, rising HbA1c, or thyroid dysfunction can mask or blunt the entire benefit.
- Choosing convenience over monitoring. A telehealth prescription with no scheduled hematocrit or PSA recheck is a liability at this age, however easy the signup was.
FAQ
Is testosterone therapy safe for men over 65?
Testosterone therapy is safe for most men over 65 when a clinician confirms deficiency with two morning draws and screens baseline PSA, hematocrit, and cardiovascular risk first. The 2023 TRAVERSE trial of more than 5,000 men found no increase in heart attack, stroke, or cardiovascular death, though it flagged higher atrial fibrillation and clotting rates that require ongoing monitoring.
What testosterone level is considered too low at 65?
Most labs flag total testosterone below roughly 300 ng/dL, combined with symptoms like fatigue, low libido, or muscle loss, as clinically low. A single reading is not enough; a second morning draw on a separate day confirms the diagnosis before treatment starts.
Does testosterone therapy increase prostate cancer risk?
Testosterone therapy does not cause prostate cancer, but it can accelerate growth in an existing undiagnosed tumor. A baseline PSA and prostate exam happen before the first prescription, with repeat PSA checks at 3 and 6 months once therapy begins.
How often should labs be rechecked on TRT after 65?
Hematocrit and PSA should be rechecked at 3, 6, and 12 months, then annually, with testosterone and estradiol checked 6 to 8 weeks after any dose change. GoodLife Health includes a full Biomarker Audit every 90 days in its membership, which matches that cadence.
Are injections or pellets better for men over 65?
Injections allow faster dose reduction if hematocrit rises, which matters more in older men carrying higher baseline clotting risk. Pellets offer convenience with infrequent dosing but cannot be reversed quickly when a side effect appears.
Can testosterone therapy help with muscle loss in older men?
Testosterone therapy can help preserve and rebuild muscle mass in men with confirmed deficiency, especially when paired with resistance training. It does not replace strength training, and men who do not lift during therapy see smaller gains in lean mass.
What disqualifies a man from testosterone therapy at 65?
Active prostate or breast cancer, uncontrolled severe heart failure, and untreated severe sleep apnea are common reasons a clinician delays or avoids starting therapy. Baseline hematocrit above the range a clinician sets as safe is another reason to wait until it is addressed.
How much does testosterone therapy cost through a membership?
GoodLife Health charges one flat monthly membership fee that covers the clinician and a quarterly Biomarker Audit, with medication billed by the pharmacy at pharmacy cost and no markup. The membership fee does not change when the dose changes.
One last thing
The detail most men over 65 miss is that testosterone therapy without resistance training changes the lab report more than it changes the body.
One last thing
The detail most men over 65 miss is that testosterone therapy without resistance training changes the lab report more than it changes the body. Muscle protein synthesis needs a mechanical stimulus to use the extra testosterone in circulation. Pair therapy with structured strength training twice a week through 2026 and the strength and lean mass gains are meaningfully larger than testosterone delivers alone.
Related guides
- Testosterone therapy for men over 50: protocol adjustments that matter
- Testosterone therapy for men concerned about prostate cancer risk
- Medical weight loss for adults over 65
References
- Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. 2018. doi.org/10.1210/jc.2018-00229